• Profile
Close

Effects of denosumab and alendronate on bone health and vascular function in hemodialysis patients: A randomized, controlled trial

Journal of Bone and Mineral Research Jun 20, 2019

Iseri K, et al. - Among 48 hemodialysis patients who were diagnosed as having osteoporosis and had not received anti-osteoporotic agents previously, researchers tested the safety and effectiveness of denosumab and alendronate. Participants in the study were randomized to either denosumab or intravenous alendronate, and during the initial 2 weeks, all subjects received elemental calcium and calcitriol. According to this prospective, three-center study, treatment with denosumab and alendronate improved lumbar spine bone mineral density, decreased bone turnover markers, and appeared safe in patients with osteoporosis with hemodialysis.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay